Oleunor N5e (Glycine, Magnesium Chloride Hexahydrate, Potassium Chloride, Calcium Chloride Dihydrate, L-Lysine Ac)

Glycine in Oleunor N5e serves as a carrier molecule that helps stabilize the solution and contributes to nitrogen transport. The primary therapeutic effect comes from the supplied ions—magnesium, potassium, calcium, and lysine acetate—which directly correct electrolyte deficits when infused into the bloodstream.

The dose of Oleunor N5e is determined by the prescribing clinician based on the patient’s electrolyte measurements, fluid status, and overall clinical condition. Healthcare professionals calculate the required volume and infusion rate to safely correct the identified deficiencies.

Limited clinical data are available for use in pregnancy and lactation. It should be administered only when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and under close medical supervision.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Oleunor N5e offers a balanced combination of glycine, magnesium, potassium, calcium, and L‑lysine acetate, providing a broader spectrum of electrolytes than some single‑ion solutions such as standard potassium chloride infusions. This multi‑ion formulation can simplify therapy when multiple deficiencies are present, though clinicians choose the product that best matches the patient’s specific electrolyte profile.

Oleunor N5e should be stored at 2‑8 °C, protected from light, and kept in its original packaging. Do not freeze or shake the solution. Before use, inspect the container for any particulate matter or discoloration and allow the product to reach room temperature if required by the administration protocol.

Oleunor N5e is administered intravenously, typically via a controlled infusion pump or gravity drip. The solution may be given undiluted or diluted according to institutional guidelines, and the infusion rate should be adjusted based on the patient’s cardiac status, renal function, and target electrolyte correction goals.

Serious risks include severe hyperkalemia or hypermagnesemia, which can lead to cardiac arrhythmias or cardiac arrest, and anaphylactic reactions. Continuous monitoring of electrolyte levels, cardiac rhythm, and patient symptoms during infusion helps mitigate these risks.

Patients with known hypersensitivity to any component of the formulation, those with existing severe hyperkalemia, uncontrolled cardiac arrhythmias, or severe renal failure where electrolyte excretion is compromised should not receive Oleunor N5e unless a specialist determines it is absolutely necessary.